Skip to main content
SpringerLink
Log in

Indikation und Differentialindikation der neuroleptischen Langzeitmedikation

  • Conference paper
Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen

Part of the book series: Tropon-Symposium ((BAYERZNS,volume 2))

Zusammenfassung

Unter neuroleptischer Langzeitmedikation wird die langdauernde, mindestens mehrmonatige Applikation von Neuroleptika verstanden. Je nach Zielsetzung dieser langdauernden Applikation von Neuroleptika kann man grundsätzlich unterscheiden zwischen (Heimchen 1979):

  1. a)

    prophylaktischer Langzeitmedikation zur Verhinderung von psychotischen Rezidiven

  2. b)

    symptomsuppressiver Langzeitmedikation zur Kupierung chronisch psychotischer Symptomatik.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abbuzzahab FS, Zimmermann RL (1982) Psychopharmacological correlates of postpsychotic depression: A double-blind investigation of haloperidol vs. thiothixene in outpatient schizophrenia. J Clin Psychiatry 43: 105–110

    Google Scholar 

  • Angst J, Bente D, Berner P, Heimann H, Heimchen H, Hippius H (1971a) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmacopsychiat Neuropsychopharmacol 4:201–211

    Google Scholar 

  • Angst J, Jaenicke H, Padrutt A, Scharfetter C (1971b) Ergebnisse eines Doppelblindversuches von Clozapin im Vergleich zu Laevomepromazin Pharmacopsychiatria 4: 192–200

    Article  CAS  Google Scholar 

  • Angst J, Woggon B (1975) Klinische Prüfung von fünf Depot-Neuroleptika. Arzneimittelforsch 25: 267–270

    PubMed  CAS  Google Scholar 

  • APA Task Fotce Report 18. Washington: American Psychiatric Press 1980

    Google Scholar 

  • Arnold OH, Collard J, Deniker P et al. (1970) Definition and classification of neuroleptics. Mod Probi Pharmacopsychiatry 5: 141–147

    CAS  Google Scholar 

  • Baldessarini RJ, Tarsy D (1978) Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York

    Google Scholar 

  • Bobon DP (1973) Classifications and terminology of psychotropic drugs. Pharmacopsychiatria 6: 1–12

    Article  CAS  Google Scholar 

  • Bobon J, Bobon DP, Pinchard A et al. (1972) A new comparative physiognomy of neuroleptics: a collaborative clinical report. Acta Psychiat Belg 72: 542–554

    CAS  Google Scholar 

  • Bobon DP, Gottfries CG (1974) Clinical physiognomy of thioxanthenes. Acta Psychiat Belg 74: 441–568

    Google Scholar 

  • Borison RL (1985) Pharmacology of antipsychotic drugs. J Clin Psychiatry 46 (4): 25–28

    PubMed  CAS  Google Scholar 

  • Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Ban TA, Berney SA (1981) A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Phar-macopsychiatria 14: 139–140

    CAS  Google Scholar 

  • Angst J, Bente D, Berner P, Heimann H, Heimchen H, Hippius H (1971a) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmacopsychiat Neuropsychopharmacol 4:201–211

    Google Scholar 

  • Bürki HR, Gaertner HJ, Breyer-Pfaff U, Schied HW (1983) Neuroleptika. Grundlagen und Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York

    Google Scholar 

  • Carpenter WT, Stephens JH, Rey AC, Hanlon TE, Heinrichs DW (1982) Early intervention vs. continuous pharmacotherapy of schizophrenia. Psychopharmacol Bull 18: 21–23

    Google Scholar 

  • Cheung HK (1981) Schizophrenics fully remitted on neuroleptic for 3–5 years — to stop or con-tinue drugs. Br J Psychiatry 138: 490–494

    Article  PubMed  CAS  Google Scholar 

  • Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137: 16

    PubMed  CAS  Google Scholar 

  • Cookson J, Silverstone T, Wells B (1981) Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiat Scand 64: 381–397

    Article  PubMed  CAS  Google Scholar 

  • Crawford R, Forest A (1974) Controlled trial of depot fluphenazine in outpatient schizophrenics. Br J Psychiatry 124: 385

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ (1978) The biochemistry of schizophrenia. Br J Hosp Med 5: 532–544

    Google Scholar 

  • Crow TJ (1981) Positive and negative schizophrenia symptoms and the role of dopamine. Br J Psychiatry 139: 252–254

    Article  Google Scholar 

  • Davis JM (1974) Dose equivalence of the antipsychotic drugs. J Psychiat Res 11: 65–69

    Article  PubMed  CAS  Google Scholar 

  • Davis JM (1976) Comparative clinical studies on antipsychotic drugs. In: Sedwall G, Urnes B, Zottermann G (eds) Pharmacodynamics and pharmacokinetics. Pergamon Press, Oxford

    Google Scholar 

  • Davis JM, Garver DL (1978) Neuroleptics: Clinical use in psychiatry. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 10. Plenum Press, New York London

    Google Scholar 

  • Davis JM, Schaffer CB, Killian GA, Kinnard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull ( Special Report: Schizophrenia )

    Google Scholar 

  • Deligné P, Bunodière M (1978) Neuroplégiques et neuroleptiques antipsychotiques. I - Définitions et classifications. Ann Anesth Franc X IX

    Google Scholar 

  • Eufe R, Wegener G (1979) Double-blind comparison of 2 depot neuroleptics (perphenazine en-anthate and flupentixol decanoate) in chronic schizophrenia. Nervenarzt 50: 534–539

    PubMed  CAS  Google Scholar 

  • Falloon I, Watt DC, Shepherd M (1978) A comparative controlled trial of pimozide and fluphen-azine decanoate in the continuation therapy of schizophrenia. Psychol Med 8: 59–70

    Article  PubMed  CAS  Google Scholar 

  • Freyhan FA (1957) Psychomotilität, extrapyramidale Syndrome und Wirkungsweisen neurolep-tischer Therapie (Chlorpromazin, Reserpin, Prochlorperazin). Nervenarzt 28: 504–509

    PubMed  CAS  Google Scholar 

  • Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation–Standard-verfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54: 467–476

    PubMed  CAS  Google Scholar 

  • Gardos G, Cole JO (1973) The importance of dosage in antipsychotic drug administration–A review of dose response studies. Psychopharmacology (Berlin) 29: 221–230

    Article  CAS  Google Scholar 

  • Gardos G, Cole JO (1976) Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry 133: 32–36

    PubMed  CAS  Google Scholar 

  • Goldberg SC, Schooler NR, Hogarty GE, Roper M (1977) Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 34: 171–184

    Article  PubMed  CAS  Google Scholar 

  • Goldstein MS, Rodnick EM, Evans JR, May PRA, Steinberg MP (1978) Drugs and family ther-apy in the after-care of acute schizophrenics. Arch Gen Psychiatry 35: 1169–1177

    Article  PubMed  CAS  Google Scholar 

  • Goodnick PJ, Meltzer HY (1984) Treatment of schizoaffective disorders. Schizophr Bull 10: 30–46

    PubMed  CAS  Google Scholar 

  • Giudice J del, Clar WG, Gocka EF (1975) Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16: 32–36

    PubMed  Google Scholar 

  • Haas S, Beckmann H (1982) Pimozide vs. haloperidol in acute schizophrenia. A double-blind controlled study. Pharmacopsychiatria 15: 70–74

    Article  PubMed  CAS  Google Scholar 

  • Heinrich H, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Erlangen, S 194–202

    Google Scholar 

  • Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 49: 534–538

    PubMed  CAS  Google Scholar 

  • Heimchen H (1979) Neuroleptische Langzeitmedikation in der Praxis. Mkurse Ärztl Fortbild 29: 800–801

    Google Scholar 

  • Hertrich O (1965) Differentialindikationen für psychosenspezifische Drogen nach Zielsymptomen. Fortschr Neurol Psychiatr 33: 49–111

    Google Scholar 

  • Herz MJ, Szymanski H, Simon JC von (1982) Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication. Am J Psychiatry 139: 918–922

    PubMed  CAS  Google Scholar 

  • Hirsch SR, Gaind R, Rohde P, Stevens B, Wing JK (1973) Outpatient maintenance treatment of chronic schizophrenic with fluphenazine decanoate injections: a double-blind placebo trial. Br Med J 41: 118–127

    Google Scholar 

  • Hogarty GE (1984) Depot-neuroleptics: The relevance of psychosocial factors–A United States perspective. J Clin Psychiatry 45: 36–42

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg S, Schooler N, Ulrich R (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. II: Two years relapse rates. Arch Gen Psychiatry 31: 603–618

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1977) Drug discontinuation among long-term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 37: 494–500

    Google Scholar 

  • Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 36: 1283–1294

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF (1977) Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 34: 297–301

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982) Fluphenazine vs. placebo in patients with remitted, ante first-episode schizophrenia. Arch Gen Psychiatry 39: 70–73

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J (1983) Low dose neuroleptic treatment of outpatient schizophrenica. Arch Gen Psychiatry 40: 893–896

    Article  PubMed  CAS  Google Scholar 

  • Kelder J (1982) Prediction of the Bobon clinical profile of neuroleptics from animal pharmacological data. Psychopharmacology (Berlin) 77: 140–145

    Article  CAS  Google Scholar 

  • Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatria 18: 240–245

    Article  CAS  Google Scholar 

  • Klein DF (1968) Importance of psychiatric diagnosis in prediction of clinical drug effect. Psycho-pharmacology (Berlin) 13: 359–386

    Article  CAS  Google Scholar 

  • Langer G, Sachar EJ, Gruen PH, Halpern F (1977) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 266: 639–645

    Article  PubMed  CAS  Google Scholar 

  • Leff J, Vaughn C (1981) The role of maintenance therapy and relatives expressed emotion in relapse of schizophrenia. A 2-year follow-up. Br J Psychiatry 139: 102–104

    Article  PubMed  CAS  Google Scholar 

  • Leff J, Wing JK (1971) Trials of maintenance therapy in schizophrenia. Br Med J 3: 559–604

    Article  Google Scholar 

  • Lehmann HE (1975) Psychopharmacological treatment of schizophrenia. Schizophr Bull 13: 27–45

    PubMed  Google Scholar 

  • Lehmann E, Hassel P, Thörner GW, Karrass W (1984) Alternatives Therapiekonzept zur Behandlung psychosomatischer Beschwerden. Fortschr Med 40: 1033–1036

    Google Scholar 

  • Lehmann E, Quadbeck H, Tegeler J, Farauni M, Heinrich K (1980) Wirkungsdifferenzen bei Hoch-and Standarddosierung von Fluphenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmakopsychiat Neuropsychopharmakol 3: 117–129

    Google Scholar 

  • Lehmann HE, Wilson WH, Deutsch M (1983) Minimal maintenance medication: effect of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Compr Psychiatry 24: 293–303

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, Putten T van, Mith J, McKenzie J, Lebell H, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029

    Article  PubMed  CAS  Google Scholar 

  • Mattes JA, Nayak D (1984) Lithium vs. fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 19: 445–449

    PubMed  CAS  Google Scholar 

  • May PRA, Goldberg SC (1978) Prediction of schizophrenia. Patients’ response to pharmacotherapy. In: Lipton MA (ed) Psychopharmacology — a generation of progress. Raven Press, New York

    Google Scholar 

  • Marder SR, Putten T van, Mith J, McKenzie J, Lebell H, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029

    Article  PubMed  CAS  Google Scholar 

  • McGonaghy N (1970) Actuarial vs. clinical prediction. Br J Psychiatry 117: 122

    Google Scholar 

  • Menter RE, Mandel MR (1979) The treatment of psychotic major disorder with drugs and electroconvulsive therapy. J Nerv Ment Dis 12: 726–733

    Google Scholar 

  • Möller HJ (1986) Methodological problems of long-term studies in psychopharmacology. Pharmacopsychiatria 19: 156–160

    Article  Google Scholar 

  • Möller HJ, Kissling W (1986) Advantages and disadvantages of depot-neuroleptics as mainte-nance medication for chronic schizophrenics. Clin Neuropharmacol 9 [Suppl] 41: 259–262

    Google Scholar 

  • Möller HJ, Zerssen D von (1986) Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Müller P (1983) Was sollen wir Schizophrenen raten? Medikamentöse Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt 54: 477–485

    PubMed  Google Scholar 

  • Nelson IC, Bowers MB (1978) Delusional unipolar depression. Description and drug response. Arch Gen Psychiatry 35: 1321–1328

    Article  PubMed  CAS  Google Scholar 

  • Niemegeers CJE (1984) Zur Pharmakologie der Antidepressiva and Neuroleptika. Nervenheilkunde 3: 28–32

    Google Scholar 

  • Niemeegers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216

    Article  Google Scholar 

  • Overall JE, Hollister LE, Johnson M (1966) Nosology of depression and differential response to drugs. JAMA 195: 946–948

    Article  PubMed  CAS  Google Scholar 

  • Overall JE, Hollister LE, Meyer F (1964) Imipramine and thioridazine in depressed and schizo-phrenic patients: are there specific antidepressant drugs? JAMA 189: 605–608

    Article  PubMed  CAS  Google Scholar 

  • Overall JE, Hollister LE, Shelton J (1969) Broad-spectrum screening of psychotherapeutic drugs: Thiothixene as an antipsychotic and antidepressant. Clin Pharmacol Ther 10: 36–43

    PubMed  CAS  Google Scholar 

  • Pach J, Wanieck W (1976) Vergleichende Untersuchung zum Tranquilizereffekt von Fluspirilene und Diazepam. Pharmakopsychiatria 9: 61–66

    Article  CAS  Google Scholar 

  • Paykel JS, Price JS, Gillan RV, Palmai G, Chesser ES (1968) A comparative trial of imipramine and chlorpromazine in depressed patients. Br J Psychiatry 114: 1281–1287

    Article  PubMed  CAS  Google Scholar 

  • Pecknold JC, McClure DJ, Allan T, Wresinski L (1982) Comparison of pimozide and chlorpromazine in acute schizophrenia. Can J Psychiatry 27: 208–212

    PubMed  CAS  Google Scholar 

  • Pietzcker A, Gaebel W, Köpcke W et al. (1986) A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatria 19: 161–166

    Article  Google Scholar 

  • Pinto R, Bannerjee A, Ghosh N (1979) A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiat Scand 60: 313–322

    Article  PubMed  CAS  Google Scholar 

  • Pöldinger W (1975) Kompendium der Psychopharmakotherapie. Privatdruck der Fa. La Roche, 3. Aufl. Basel 1975

    Google Scholar 

  • Pöldinger W, Sieberns S (1983) Depression-inducing and antidepressive effects of neuroleptics. Experiences with flupenthixol and flupenthixol-decanoate. Neuropsychobiology 10: 131–136

    Article  PubMed  Google Scholar 

  • Puech A, Lecrubier Y, Simon P (1984) Pharmacological classification of benzamides. Acta Psychiat Scand [Suppl] 311: 139–145

    Article  CAS  Google Scholar 

  • Raskin A, Schulterbrandt JG, Reating N, Chase C, McKeon JJ (1970) Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry 23: 154–173

    Article  Google Scholar 

  • Rifkin A, Quitkin F, Klein DF (1975) Akinesia: A poorly recognized drug induced extrapyramidal disorder. Arch Gen Psychiatry 32: 672–674

    Article  Google Scholar 

  • Robertson MM, Trimble MR (1982) Major tranquilizers used as antidepressants. A review. J Affect Disord 4: 173–193

    Article  PubMed  CAS  Google Scholar 

  • Schmidt LG, Schüssler G, Kappes U, Mühlbauer H, Müller-Oerlinghausen B (1982) A double-blind study of the antipsychotic efficacy of perazine compared to haloperidol. Arzneimittelforsch 32: 910–911

    Google Scholar 

  • Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37: 16–24

    Article  PubMed  CAS  Google Scholar 

  • Schooler NR, Severe J, Levine J et al. (1980) Der Abbruch der neuroleptischen Behandlung bei schizophrenen Patienten und dessen Einfluß auf Rückfälle und auf Symptome der Spätdyskinesie? In: Kryspin-Exner, Hinterhuber H, Schubert H (Hrsg) Ergebnisse der psychiatrischen Therapieforschung. Schattauer, Stuttgart New York

    Google Scholar 

  • Seeman P, Tittler M, Tedesco J, Lee T (1977) Neuroleptic sites of membrane action: Non-specific (anesthetic) and specific dopamine receptors. In: Keverling-Buisman JA (ed) Biological activity and chemical structure. Elsevier, Amsterdam Oxford New York

    Google Scholar 

  • Sieberns S (1986) Darstellung der Depotneuroleptika. In: Heinrich K, Sieberns S (Hrsg) Das ärztliche Gespräch 40. Internationales Fluanxol-Depot-Kolloquium. pmi Verlag, Frankfurt

    Google Scholar 

  • Simon P, Fermanian J, Ginestedt D (1978) Standard and long acting depot neuroleptics in chronic schizophrenics. Arch Gen Psychiatry 35: 893–897

    Article  PubMed  CAS  Google Scholar 

  • Simon P, Lecrubier Y, Puech AJ (1984) Classification des neuroleptiques. Rev Pract 34 (13): 589–594

    CAS  Google Scholar 

  • Simpson GM, Amin M, Angus JWS, Edwards JG, Hing Go S, Lee JH (1972) Role of antidepressants and neuroleptics in the treatment of depression. Arch Gen Psychiatry 27: 337–345

    Article  PubMed  CAS  Google Scholar 

  • Simpson GM, Watts TPS (1965) Antidepressant drugs. Am J Psychiatry 121: 1028–1029

    PubMed  CAS  Google Scholar 

  • Spiker DG, Hanin I, Perel JM, Cofsky JE, Rossi AJ, Sorisio D (1982) Pharmacological treatment of delusional depressives. Psychopharmacol Bull 18: 184–186

    PubMed  CAS  Google Scholar 

  • Spiker DG, Weiss JC, Dealy RC et al. (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430–436

    PubMed  CAS  Google Scholar 

  • Stumpf C (1978) Pharmakologie der Psychopharmaka. Dtsch Apothek Ztg 39: 1405–1410

    Google Scholar 

  • Tansella M, Balestrieri A (1976) The choice of neuroleptics in the treatment of schizophrenia. Arzneimittelforsch 26: 943–945

    PubMed  CAS  Google Scholar 

  • Task Force on late neurological effects of antipsychotic drugs (1980) Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137: 1163–1172

    Google Scholar 

  • Tegeler J (1981) Dosierung und Verträglichkeit der Depot-und Langzeitneuroleptika. In: Das ärztliche Gespräch 35. Erfahrungsaustausch über die Anwendung von Depotneuroleptika — unter besonderer Berücksichtigung der Thioxanthen-Depotneuroleptika. Kolloquium der Tropon-Werke 1981

    Google Scholar 

  • Tegeler J, Floru L (1979) Eine vergleichende Untersuchung der Depot-Neuroleptika Perphenazin Önanthat und Fluspirilen. Pharmakopsychiatria 12: 257–265

    Article  Google Scholar 

  • Vaughn CE, Snyder KS, Freeman W (1982) Family factors in schizophrenic relapse: a replication. Schizophr Bull 8: 425–426

    PubMed  CAS  Google Scholar 

  • Winter K, Fullerton AG, Hussain K, Tarlo L (1973) A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia. Br J Clin Pract 27: 377–380

    PubMed  CAS  Google Scholar 

  • Woggon B, Angst J, Margoses N (1975) Gegenwärtiger Stand der neuroleptischen Langzeitbehandlung der Schizophrenie. Nervenarzt 46: 611–616

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 24, rue des Fossés Saint Jacques, F-75005, Paris, France

    Pierre Pichot

  2. Psychiatrische Klinik der Technischen Universität, Ismaninger Str. 22, D-8000, München 80, Deutschland

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Möller, H.J. (1987). Indikation und Differentialindikation der neuroleptischen Langzeitmedikation. In: Pichot, P., Möller, HJ. (eds) Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen. Tropon-Symposium, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83188-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83188-1_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18197-2

  • Online ISBN: 978-3-642-83188-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation